Literature DB >> 34319502

Comparison of effects of tamsulosin and silodosin on subfoveal choroidal thickness and pupil size diameters in patients with prostatic hyperplasia.

Hatice Selen Kanar1, Mahmut Taha Olcucu2, Ibrahim Ozdemir3.   

Abstract

PURPOSE: To compare the effects of selective α-1 adrenoceptor antagonists on subfoveal choroidal thickness (SFCT) and pupil diameter size (PDS).
METHODS: This prospective study included 87 patients diagnosed with benign prostatic hyperplasia who were treated with tamsulosin hydrochloride (n = 41) or silodosin (n = 46). SFCT measurements were obtained using spectral domain optic coherence tomography (SD-OCT), and PDS measurements were obtained under mesopic, photopic and scotopic conditions using a photography-based topography system. SFCT and PDS were evaluated at baseline and 3-, 6- and 12-mo follow-ups.
RESULTS: The initial mean SFCT was 270.53 ± 21.48 µm in tamsulosin group and 271.95 ± 24. 73 in silodosin group (P = 0.078). There was no statistically significant change in SFCT at the 3-mo visit. At the 6-mo follow-up, the mean SFCT was 281.34 ± 22.09 µm in tamsulosin group and 272.5 ± 22.4 µm in silodosin group. At the 12th month, the mean SFCT in tamsulosin group was 290.80 ± 17.27 µm, and it was 270.80 ± 13.14 µm in silodosin group. There was statistically significant difference in at 6th and 12-mo visits (P = 0.014 and P = 0.00). During the follow-up, both drugs induced a similar significant decrease in PDS under all conditions.
CONCLUSIONS: Tamsulosin hydrochloride caused a significant increase in SFCT. In contrast, SFCT did not increase in silodosin group. The decreases in PDS achieved using both drugs were similar. This should be kept in mind when choroidal disease and its response to treatment are followed by CT imaging.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Pupil diameter size; Silodosin; Spectral domain optic coherence tomography; Subfoveal choroidal thickness; Tamsulosin

Year:  2021        PMID: 34319502     DOI: 10.1007/s10792-021-01961-4

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  18 in total

1.  Distribution of alpha-1 adrenoceptor subtypes in RNA and protein in rabbit eyes.

Authors:  Fumiko Suzuki; Takanobu Taniguchi; Seigo Nakamura; Yoshio Akagi; Chikara Kubota; Makoto Satoh; Ikunobu Muramatsu
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

Review 2.  The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: alpha-blockers in the treatment of male voiding dysfunction - how do they work and why do they differ in tolerability?

Authors:  Martin C Michel
Journal:  J Pharmacol Sci       Date:  2010-02-04       Impact factor: 3.337

Review 3.  Epidemiology and treatment modalities for the management of benign prostatic hyperplasia.

Authors:  Soum D Lokeshwar; Benjamin T Harper; Eric Webb; Andre Jordan; Thomas A Dykes; Durwood E Neal; Martha K Terris; Zachary Klaassen
Journal:  Transl Androl Urol       Date:  2019-10

4.  Intraoperative floppy iris syndrome associated with tamsulosin.

Authors:  David F Chang; John R Campbell
Journal:  J Cataract Refract Surg       Date:  2005-04       Impact factor: 3.351

5.  Medical management of benign prostatic hyperplasia: Results from a population-based study.

Authors:  Mohamed Bishr; Katharina Boehm; Vincent Trudeau; Zhe Tian; Paolo Dell'Oglio; Jonas Schiffmann; Claudio Jeldres; Maxine Sun; Sharokh F Shariat; Markus Graefen; Fred Saad; Pierre I Karakiewicz
Journal:  Can Urol Assoc J       Date:  2016 Jan-Feb       Impact factor: 1.862

6.  The impact of self-management of lower urinary tract symptoms on frequency-volume chart measures.

Authors:  Tet L Yap; Christian Brown; David A Cromwell; Jan van der Meulen; Mark Emberton
Journal:  BJU Int       Date:  2009-05-25       Impact factor: 5.588

7.  KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues.

Authors:  K Shibata; R Foglar; K Horie; K Obika; A Sakamoto; S Ogawa; G Tsujimoto
Journal:  Mol Pharmacol       Date:  1995-08       Impact factor: 4.436

Review 8.  Cardiovascular and ocular safety of α1-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms.

Authors:  Matthias Oelke; Adrian Gericke; Martin C Michel
Journal:  Expert Opin Drug Saf       Date:  2014-07-29       Impact factor: 4.250

Review 9.  The Choroid and Optical Coherence Tomography.

Authors:  Taha Sezer; Muhammet Altınışık; İbrahim Arif Koytak; Mehmet Hakan Özdemir
Journal:  Turk J Ophthalmol       Date:  2016-01-05

Review 10.  Ten years of intraoperative floppy iris syndrome in the era of α-blockers.

Authors:  Andreas Lunacek; Badereddin Mohamad Al-Ali; Christian Radmayr; Maria Weber; Wolfgang Horninger; Oliver Findl; Eugen Plas
Journal:  Cent European J Urol       Date:  2017-12-06
View more
  1 in total

1.  Risk of intraoperative floppy iris syndrome among selective alpha-1 blockers-A consistency model of 6,488 cases.

Authors:  Ya-Hui Wang; Liang-Chen Huang; Sung Huang Laurent Tsai; Ying-Jen Chen; Chien-Liang Wu; Yi-No Kang
Journal:  Front Med (Lausanne)       Date:  2022-08-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.